The vaccine in question, called ABNCoV2, was developed by the Danish Expres2ion Biotechnologies, in collaboration with the other consortium partners. The development of the vaccine has now reached the point where it is ready to be tested in humans. This clinical study will take place in the Netherlands. A backup vaccine has also been made by researchers at Wageningen University. This backup vaccine is currently in the preclinical phase.
By: National Education Guide